European Biotech Reviews Need FDA-Style "Transparency" - E&Y Report
Executive Summary
The European biotechnology industry is being hampered by a lack of FDA-style "transparency" in product reviews, Ernst & Young maintained in its report, "European Life Sciences 98: Continental Shift," released April 28 at the Ernst & Young/Atlas Ventures life sciences conference in Amsterdam.